Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS)
CNY 23.6
(-0.3%)
CNY 23.6
(-0.3%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 150.45 Million CNY | 48.24% |
| 2022 | 101.49 Million CNY | -31.42% |
| 2021 | 147.98 Million CNY | -19.29% |
| 2020 | 183.35 Million CNY | -31.09% |
| 2019 | 266.08 Million CNY | 0.81% |
| 2018 | 263.92 Million CNY | -44.88% |
| 2017 | 478.81 Million CNY | 149.84% |
| 2016 | 191.65 Million CNY | -1.84% |
| 2015 | 195.25 Million CNY | 11.0% |
| 2014 | 175.89 Million CNY | 48.52% |
| 2013 | 118.43 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 37.54 Million CNY | -9.86% |
| 2024 Q1 | 41.65 Million CNY | 436.24% |
| 2024 Q3 | 33.77 Million CNY | -10.06% |
| 2023 FY | 150.45 Million CNY | 48.24% |
| 2023 Q3 | 55.74 Million CNY | -17.07% |
| 2023 Q2 | 67.22 Million CNY | 161.88% |
| 2023 Q1 | 25.66 Million CNY | 173.94% |
| 2023 Q4 | -12.38 Million CNY | -122.22% |
| 2022 Q2 | 35.6 Million CNY | -23.33% |
| 2022 Q1 | 46.43 Million CNY | 331.24% |
| 2022 FY | 101.49 Million CNY | -31.42% |
| 2022 Q4 | 9.37 Million CNY | -56.68% |
| 2022 Q3 | 21.63 Million CNY | -39.24% |
| 2021 Q2 | 35.62 Million CNY | -44.67% |
| 2021 Q1 | 64.39 Million CNY | 54.79% |
| 2021 Q3 | 37.19 Million CNY | 4.4% |
| 2021 Q4 | 10.76 Million CNY | -71.05% |
| 2021 FY | 147.98 Million CNY | -19.29% |
| 2020 FY | 183.35 Million CNY | -31.09% |
| 2020 Q4 | 41.6 Million CNY | 7.49% |
| 2020 Q2 | 70.82 Million CNY | 119.72% |
| 2020 Q1 | 32.23 Million CNY | -48.33% |
| 2020 Q3 | 38.7 Million CNY | -45.35% |
| 2019 Q3 | 54.29 Million CNY | -45.82% |
| 2019 Q1 | 49.17 Million CNY | -54.04% |
| 2019 FY | 266.08 Million CNY | 0.81% |
| 2019 Q4 | 62.38 Million CNY | 14.89% |
| 2019 Q2 | 100.22 Million CNY | 103.83% |
| 2018 Q2 | 60.23 Million CNY | 49.57% |
| 2018 FY | 263.92 Million CNY | -44.88% |
| 2018 Q4 | 106.99 Million CNY | 89.58% |
| 2018 Q3 | 56.43 Million CNY | -6.3% |
| 2018 Q1 | 40.26 Million CNY | -30.81% |
| 2017 FY | 478.81 Million CNY | 149.84% |
| 2017 Q3 | 36.44 Million CNY | 0.0% |
| 2017 Q4 | 58.19 Million CNY | 59.71% |
| 2016 FY | 191.65 Million CNY | -1.84% |
| 2015 FY | 195.25 Million CNY | 11.0% |
| 2014 FY | 175.89 Million CNY | 48.52% |
| 2013 FY | 118.43 Million CNY | 0.0% |